Amiodarone-induced thyreopaties
Authors:
Adela Krausová
Authors‘ workplace:
3. interní klinika – klinika endokrinologie a metabolismu 1. LF UK a VFN v Praze
Published in:
Čas. Lék. čes. 2025; 164: 94-99
Category:
Review Article
Overview
Amiodarone-induced thyroid dysfunction represents a serious complication of treatment with amiodarone, a frequently used potent antiarrhythmic drug. In clinical practice, there are two main forms: hypothyroidism and hyperthyroidism. Amiodarone-induced thyrotoxicosis is further divided into type 1 and type 2 with different pathogenesis, diagnostic findings and, most importantly for the patient, therapeutic approach. Due to frequent diagnostic overlap, a mixed form of amiodarone-induced thyrotoxicosis is also recognized, requiring a combination of both distinct treatment strategies, antithyroid drugs and glucocorticoids.
Amiodarone-induced type 1 thyrotoxicosis necessitates prospective discontinuation of amiodarone therapy; in type 2 this step is usually not warranted. In hypothyroidism, substitution therapy with levothyroxine is sufficient without the need to stop antiarrhythmic treatment with amiodarone. Amiodarone-induced thyrotoxicosis may significantly increase the incidence of cardiovascular complications. If amiodarone treatment is discontinued solely for cardiological indications, patients without a history of thyroid disease usually experience restoration of normal thyroid function. However, in predisposed individuals, dysfunction may persist or recur following repeated iodine exposure.
Keywords:
amiodarone, thyroid gland; thyroid dysfunction, hypothyroidism, thyrotoxicosis
Sources
- Ross DS. Amiodarone and thyroid dysfunction. UpToDate, 2024. Dostupné na: www.uptodate.com/contents/amiodarone-and-thyroid-dysfunction
- Trip MD, Wiersinga W, Plomp TA. Incidence, predictability, and pathogenesis of amiodarone-induced thyrotoxicosis and hypothyroidism. Am J Med 1991; 91: 507–511.
- Harjai KJ, Licata AA. Effects of amiodarone on thyroid function. Ann Intern Med 1997; 126: 63–73.
- Martino E, Safran M, Aghini-Lombardi F et al. Environmental iodine intake and thyroid dysfunction during chronic amiodarone therapy. Ann Intern Med 1984; 101: 28–34.
- Basaria S, Cooper DS. Amiodarone and the thyroid. Am J Med 2005; 118: 706–714.
- Ross DS, Burch HB, Cooper DS et al. 2016 American Thyroid Association Guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 2016; 26: 1343–1421.
- Yiu KH, Jim MH, Siu CW et al. Amiodarone-induced thyrotoxicosis is a predictor of adverse cardiovascular outcome. J Clin Endocrinol Metab 2009; 94: 109–114.
- O’Sullivan AJ, Lewis M, Diamond T. Amiodarone-induced thyrotoxicosis: left ventricular dysfunction is associated with increased mortality. Eur J Endocrinol 2006; 154: 533–536.
- Tomisti L, Rossi G, Bartalena L et al. The onset time of amiodarone-induced thyrotoxicosis (AIT) depends on AIT type. Eur J Endocrinol 2014; 171: 363–368.
- Bartalena L, Chiovato L, Croce L et al. Management of amiodarone-associated thyroid dysfunction: an expert consensus statement from the European Thyroid Association (ETA). Eur Thyroid J 2018; 7: 55–66.
Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management Dental HygienistArticle was published in
Journal of Czech Physicians
Most read in this issue
- Shooting at the Faculty of Arts of Charles University and activation of the trauma plan at the First Surgical Clinic of the General Teaching Hospital
- Amiodarone-induced thyreopaties
- Clinical obesity – finally a change of paradigm? From BMI to chronic disease
- Comparison of performance between artificial intelligence and radiologists in detecting abnormalities on chest X-rays